Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.59 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | TK2 | O00142 | 11/20 | 0.43 |
| ▸ | TK1 | P04183 | 1/20 | 0.42 |
| ▸ | DUT | P33316 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008546 | 0.94 | KIF11 (0.57) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL17377651 | 0.92 | KIF11 (0.55) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL913220 | 0.92 | KIF11 (0.55) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL20032419 | 0.92 | KIF11 (0.55) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL4012213 | 0.87 | KIF11 (0.63) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL6891571 | 0.87 | KIF11 (0.48) | KIF11HRH4TK2SLC6A1 | |
| SCHEMBL11275984 | 0.82 | KIF11 (0.74) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL7050159 | 0.81 | KIF11 (0.40) | KIF11HRH4TK2TK1SLC6A1 | |
| SCHEMBL16223048 | 0.80 | KIF11 (0.55) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL2489713 | 0.79 | KIF11 (0.59) | KIF11HRH4TK2TK1DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-01-30 | — | — | US | disclosed |
| WO-2023059583-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| WO-2022071286-A1 | LIQUID-CRYSTAL COMPOSITION, LIQUID-CRYSTAL DISPLAY ELEMENT PRODUCTION METHOD, AND LIQUID-CRYSTAL DISPLAY ELEMENT | 日産化学株式会社 | 2022-04-07 | — | — | WO | disclosed |
| CN-102378753-B | Plasminogen activator-1 inhibitor | RENASCIENCE Co.,Ltd. (JP) | 2016-03-02 | — | — | CN | disclosed |
| CN-102378753-A | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO LTD | 2012-03-14 | — | — | CN | disclosed |
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-20110021459-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-7795270-B2 | DUTPase inhibitors | MEDIVIR AB (SE) | 2010-09-14 | — | — | US | disclosed |
| EP-2074126-A2 | SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20080312183-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080096903-A1 | SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-04-24 | — | — | US | disclosed |
| WO-2008049105-A2 | SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-04-24 | — | — | WO | disclosed |
| EP-1701727-A1 | DUTPASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005065689-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| US-5998624-A | MEDICAL DIAGNOSIS; BINDING TO SITE OF INJURY, INFLAMMATION | EMORY UNIVERSITY (US) | 1999-12-07 | — | — | US | disclosed |
| US-5908863-A | ANTIGROWTH AGENT FOR BONES | DOMPE' S.P.A. (IT) | 1999-06-01 | — | — | US | disclosed |
| WO-1998049900-A1 | HALOISOQUINOLINE CARBOXAMIDE | EMORY UNIVERSITY (US) | 1998-11-12 | — | — | WO | disclosed |
| EP-0792878-A2 | Geminal carboxylic acids and esters thereof, pharmaceutical formulations containing them useful in the treatment of bone dysmetabolism | Dompé S.P.A. (IT) | 1997-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312183-A1 | Dutpase Inhibitors | DUT, DHODH, RNASEH1 | KIF11 2729/4885HRH4 169/4885TK2 224/4885 |
| US-20110021459-A1 | DUTPASE INHIBITORS | DUT, DHODH, NAT10 | KIF11 2686/4885HRH4 179/4885TK2 259/4885 |
| US-20080096903-A1 | SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF | HSP90AB2P, HSP90AB1, HSP90AA1 | KIF11 3711/4885HRH4 3079/4885TK2 1154/4885 |
| US-20250032623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | AURKB, CDK9, AURKA | KIF11 39/4885HRH4 2182/4885TK2 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.